Tag: Biosciences
Novartis: Strategic collaboration with Lindy Biosciences
(CercleFinance.com) – American biotech Lindy Biosciences announced on Wednesday that it had entered into a strategic collaboration agreement with Novartis, which is interested in its drug self-injection technology. In a…
NFL Biosciences: Why, despite positive results in smoking cessation, NFL Biosciences is falling on the stock market
(BFM Bourse) – The biopharmaceutical company announced results from its phase 2 clinical study highlighting the efficacy of NFL-101 for smoking cessation comparable to that of Champix, but without its…
NFL Biosciences: Invest Securities raises its target
(CercleFinance.com) – Invest Securities confirms its buy rating on the NFL Biosciences stock with a price target raised from 5.5 to 8.8 euros. The analyst reports that the results of…
NFL Biosciences: Successful clinical trial of smoking cessation drug candidate NFL-101 – 07/15/2024 at 10:11
(AOF) – NFL Biosciences (-8.24% at 2.56 euros) announces the success of its phase 2 clinical study, Cesto II, of NFL-101, its drug candidate for smoking cessation. This biotech company…
NFL Biosciences: Successful clinical trial of smoking cessation drug candidate NFL-101
(AOF) – NFL Biosciences (-8.24% at 2.56 euros) announces the success of its phase 2 clinical study, Cesto II, of NFL-101, its drug candidate for smoking cessation. This biotech company…
NFL Biosciences: Potential confirmed in smoking cessation – 07/15/2024 at 12:17 p.m.
(CercleFinance.com) – NFL Biosciences experienced some profit taking on Monday morning despite the announcement of satisfactory results in its phase 2 clinical study devoted to smoking cessation. The biopharmaceutical company…
NFL BIOSCIENCES: scientific publication of the study on the mechanism of action of NFL-101 carried out by the CEA in ACS Chemical Neuroscience – 06/17/2024 at 11:00
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, announces the publication in an international peer-reviewed scientific journal, today,…
Nfl biosciences: The study with the CEA presented at a conference
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
NFL Biosciences: the study with the CEA presented at the conference – 05/29/2024 at 12:20 p.m.
(CercleFinance.com) – NFL Biosciences announced on Wednesday its intention to present the results of its study conducted with the CEA at the Albatross congress, an upcoming event dedicated to the…
AstraZeneca: License agreement concluded with Nona Biosciences
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
NFL Biosciences: success of the capital increase
(CercleFinance.com) – NFL Biosciences announced on Friday that it had successfully completed its capital increase for an amount of more than three million euros. The biopharmaceutical company, which develops botanical…
NFL Biosciences raises some 3 million euros through capital increases – 04/11/2024 at 6:10 p.m.
(AOF) – NFL Biosciences announces that some 3 million euros will be raised in the form of capital increases. The biotech developing botanical medicines for the treatment of dependencies and…